Introduction to SFTCG 2009

Abstract

SFTCG Board and Organizing Committee

François Lemoine (President)	Olivier Boyer
Nicolas Ferry (Vice-President)	Alberto Epstein
Nathalie Cartier-Lacave (Vice-President)	Pierre Lehn
Anne Dubart-Kupperschmitt (Secretary)	Patrick Midoux
Sophie Gomez (Webmaster)	Anna Salvetti
Martine Guigon (Treasurer)	Daniel Scherman
Anne Galy (Vice-Treasurer)	Anne Weber

Sponsors for the 8^th annual meeting of the SFTCG

Platinium sponsors	Gold sponsors	Silver sponsors
INSERM	Beckman Coulter Genosafe	Promega
THERMO SCIENTIFIC	Inserm Transfert Millipore	Transgene
AFM	Miltenyi Biotec Peprotech	Vectalys
	Plasmid FactorySigma Aldrich

8^th Annual Meeting of the “French Society of Cell and Gene Therapy” Paris, June 21–23, 2009

Programme

Sunday June 21

11h30		Opening ceremony
11h45–12h30		Special lecture (1):
11h45–12h30	• Inv1	Rudolf JAENISCH The Whitehead Institute and MIT, Cambridge, MA, USA“Stem cells, pluripotency and nuclear reprogramming”
12h30–14h00		LUNCH
14h–16h		Cell therapy session
	• Inv2	Michel PUCéAT INSERM Avenir Program, Campus Genopole 1, Evry, France“Early primate multipotent cardiovascular progenitors derived from pluripotent stem cells safely engraft in postmyocardial infarcted primate: A proof of principle in regenerative medicine”
	• Inv3	Emmanuelle CHARAFE-JAUFFRET Biopathologie, Centre de Recherche en Cancérologie, Marseille, France “Tumor stem cells mediate the metastatic phenotype in inflammatory breast cancer”
	Selected oral presentations
	• Or1	Rima Haddad INSERM U935, University Paris 11, Villejuif, France “Induction of hematopoiesis in human induced pluripotent stem cells in comparison with human embryonic stem cells”
	• Or2	Thomas Touboul INSERM U972, Université Paris 11, Hôpital Kremlin-Bicêtre, France “Generation of hepatocytes from human embryonic stem cells: in vitro and in vivo functional studies”
	• Or3	Yamina Hamel CNRS UMR 7211 & Université Pierre et Marie Curie-Paris 6, Paris, France “Preparation of human alloantigen-specific natural regulatory T-cells”
16h–16h30		Coffee Break
16h30–18h30		Vectorology session
	• Inv4	Nicolas MERMOD University of Lausanne, Lausanne, Switzerland“Characterization of insulators and barrier elements for gene therapy”
	• Inv5	Axel RETHWILM Institut für Virologie und Immunbiologie, Würzburg, Germany.“Development of foamy virus vectors”
	Selected oral presentations
	• Or4	Agathe Eckenfelder Inserm U781, Hôpital Necker-Enfants Malades, Paris, France “U7snRNA optimization for expression of therapeutic antisense sequences”
	• Or5	Cecilia Frecha Inserm U758, Ecole Normale Supérieure de Lyon, Université Lyon 1, France “Measles virus gp pseudotyped LVs allow efficient transduction of quiescent B-cells by using a highway to the nucleus”
	• Or6	Anthony Delalande UPR 4301 CNRS, Université d'Orléans, Inserm U930, Tours, France “Ultrasound-assisted microbubbles mediates long-term gene expression in Achilles tendon”
18h30–19h15		Special lecture (2):
18h30–19h15	• Inv6	David KLATZMANN Immunology-Immunopathology-Immunotherapy (I3), UPMC, Cnrs, Inserm, Paris, France“Of Treg and therapy”
19h15–21h00		Poster session (viewing) & welcome reception

Monday June 22

8h30–11h00		Vaccinology-Immunotherapy-Infectious diseases
	• Inv7	Mary COLLINS Infection and Immunity, University College London, London, UK“Lentiviral vectors as vaccines”
	• Inv8	Claude LECLERC Immune Regulation and Vaccinology, Institut Pasteur, Inserm U833, Paris, France“Treatment of large established tumors by combined immunotherapy targeting adaptive and regulatory responses”
	• Inv9	François-Loïc COSSET Université de Lyon 1, Inserm U758, ENS de Lyon, Lyon, France“Engineering and vectorization of virus-like particles (VLPs) as novel vaccines to combat acute and chronic infectious diseases”
	Selected oral presentations
	• Or7	Florence Boisgérault INSERM U951, GENETHON, Evry, France “Administration of miRNA 142.3 p-regulated rAAV2/1 vectors in skeletal muscle reduces the initial anti-transgene immune response”
	• Or8	Céline Terrada UPMC, CNRS UMR7211, INSERM U959, CERVI, Paris, France “Cellular therapy using regulatory T cells in uveitis”
	• Or9	Gilles Marodon CNRS UMR 7211 & Université Pierre et Marie Curie-Paris6, Paris, France “Towards HIV gene therapy in humanized mice”
11h00–11h30		Coffee Break
11h30–13h30		Session on clinical trials
	• Inv10	Robin R. ALI Institute of Ophtalmology, University College London, London, UK“Gene therapy for inherited retinal degeneration: from mouse to man”
	• Inv11	Gillian BUTLER-BROWNE UMR S 974, Inserm, UPMC, Institut de Myologie; UMR 7215 CNRS, Paris, France“Oculopharyngeal muscular dystrophy (OPMD): a good candidate for myoblast transplantation”
	Selected oral presentations
	• Or10	Tuan Huy Nguyen INSERM U948, Biothérapies Hépatiques, EA4274, Nantes, France “Long-term and complete correction of hyperbilirubinemia in immunocompetent adult Gunn rats by in vivo lentiviral gene delivery”
	• Or11	Matthias Titeux INSERM, U563, Université Toulouse III Paul Sabatier, Toulouse, France “Exon skipping gene therapy for Dystrophic Epidermolysis Bullosa”
	• Or12	Maciej Malecki Centre of Oncology, 02–781 Warsaw, 5 Roentgen str., Poland “Antiangiogenic gene therapy: an application of plasmid vector encoding soluble FLT-1 receptor for locally advanced vulvar cancer”
13h30–15h00		POSTER SESSION (presentations) & LUNCH
15h00–16h00		General Assembly of SFTCG
	THERMO FISHER SCIENTIFIC award
16h00–18h00		Session on new gene therapy approaches
	• Inv12	Florence APPARAILLY Inserm U844, Université Montpellier 1, CHU Lapeyronie, Montpellier, France“In vivo RNAi for successful design of alternative therapies in autoimmunity”
	• Inv13	Annemieke AARTSMA-RUS Leiden University Medical Center, Leiden, The Netherlands“Antisense-mediated exon skipping for Duchenne Muscular Dystrophy”
	Selected oral presentations
	• Or13	Trevor N. Collingwood Sigma Aldrich R&D, Saint Louis, MO, US “Targeted Genome Editing in Mammalian Cells Using Engineered Zinc Finger Nucleases”
	• Or14	Monique Bolotin-Fukuhara Institut de Génétique et Microbiologie, UMR 8621, Orsay, France “Upstream of gene therapy: yeast as a tool to select correcting genes”
	• Or15	William Lostal Généthon, CNRS FRE3087, Evry, France “Efficient in vivo dysferlin expression by dual AAV vectors reconstruction”
	• Or16	Johannes Fruehauf Cequent Pharmaceuticals Inc., Boston, MA, USA “Development of a therapeutic RNAi delivery system using nonpathogenic bacteria expressing inv and hly: transkingdom RNA interference (tkRNAi)”

Tuesday June 23

Special thematic session:	“BIOSAFETY IN CELL AND GENE THERAPY”
8h30–10h30		Retroviral vectors and insertional mutagenesis
	• Inv14	Alain FISCHER Inserm U768, Hôpital Necker, Université Paris Descartes, Paris, France“Gene therapy of SCID: a 10-year survey”
	• Inv15	Christopher BAUM Experimental hematology, Hannover Medical School, Hannover, Germany“Retroviral vectors and insertional mutagenesis”
	• Inv16	Jean-Christophe PAGèS Inserm U966, Université de Tours, Tours, France“Which model to measure vector-induced integration risk? A regulatory perspective”
Round table
10h30–11h00		Coffee Break
11H00–13h00		Chromosomal instability and mesenchymal stem cells
	• Inv17	Luc SENSEBé Etablissement français du sang (EFS), Tours, France“Clinical-grade Mesenchymal Stem Cells: aneuploidy is not transformation”
	• Inv18	Jean- Paul RENARD UMR Biologie du développement et reproduction, INRA, Jouy en Josas, France“Reprogramming somatic nuclei into embryonic nuclei through nuclear transfer and the stem cell potential of the derived cell lines”
	• Inv19	Sophie LUCAS AFSSAPS (French Health Products Agency), Saint Denis, France“Chromosomal instability and mesenchymal stem cells”
Round table
13H00–14h30		LUNCH
14H00–16h00		Use of viral particles in gene therapy and vaccination: Immunological consequences
	• Inv20	Jim WILSON University of Pennsylvania, Philadelphia, USA“Immune reactions to Adenovirus and AAV (natural infection and viral vectors)”
	• Inv21	Philippe MOULLIER INSERM UMR 649, CHU de Nantes, Université de Nantes, Nantes, France“Mode of delivery and cell tropism vs immunotoxicity of recombinant AAV in nonhuman primate”
	• Inv22	Isabelle RICHARD Généthon, Evry, France“AAV-mediated gene transfer in limb-girdle muscular dystrophies: complex strategies and biosafety issues”
Round table
Concluding remarks about biosafety in cell and gene therapy
Jean-Hugues TROUVIN, AGEPS, Paris, France
16H00–16h30	Best oral presentation and best poster awards
Closure

Introduction to SFTCG 2009

Abstract

SFTCG Board and Organizing Committee

Sponsors for the 8th annual meeting of the SFTCG

8th Annual Meeting of the “French Society of Cell and Gene Therapy” Paris, June 21–23, 2009

Programme

Sunday June 21

Monday June 22

Tuesday June 23

Sponsors for the 8^th annual meeting of the SFTCG

8^th Annual Meeting of the “French Society of Cell and Gene Therapy” Paris, June 21–23, 2009